新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2024-090 （2）网络投票时间：2024 年 11 月 4 日 其中，通过深圳证券交易所交易系统进行网络投票的时间为：2024 年 11 月 4 日 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深圳证券交易所互联网投票系统 进行网络投票的时间为：2024 年 11 月 4 日 9:15 至 15:00 期间的任意时间。 新里程健康科技集团股份有限公司 2024年第五次临时股东大会决议公告 特别提示： 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 1、本次股东大会无否决提案的情形。 2、本次股东大会无涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间 （1）现场会议时间：2024年11月4日（星期一）下午14:50开始 公司董事、监事及高级管理人员出席了本次股东大会，北京市中伦律师事务 所见证律师列席了本次股东大会。 二、议案审议表决情况 2、会议召开地点：北京市朝阳区东三环中路5号财富金融中心29层 ...

Financial Performance - The company achieved a revenue of 2.68 billion CNY in the first three quarters, representing a year-on-year growth of 6.9% [2] - The traditional Chinese medicine segment generated 590 million CNY, with a significant growth of 50% [2] - The net profit attributable to the parent company was 52.79 million CNY, up 58% year-on-year, with a non-recurring net profit of 47.78 million CNY, reflecting a 61% increase [2] - Operating cash flow reached 180 million CNY, and the net assets attributable to the parent company stood at 2.31 billion CNY, both showing year-on-year growth [2] Revenue Breakdown - Revenue from the medical services segment was 2.09 billion CNY, while the pharmaceutical segment contributed 590 million CNY [2] - Outpatient visits totaled approximately 2.23 million, marking a 4% increase, while inpatient admissions remained stable at around 180,000 [2] - The revenue ratio of outpatient to inpatient services was approximately 3:7 [2] Medical Insurance and Bad Debt - Medical insurance revenue accounted for about 50% of the medical services segment, with a bad debt ratio of less than 5%, showing stability compared to the previous year [2] - Drug costs represented approximately 26% of total expenses, while consumables accounted for about 14% [2] Strategic Development - The company aims to establish a regional center in Chongqing with projected revenue of 800-1,000 million CNY, leveraging its geographical advantages [3] - The company plans to continue asset injections, focusing on compliance, reasonable valuation, profitability, and growth potential [3] - The "1+N" strategy aims to create a comprehensive healthcare network integrating elderly hospitals, care centers, and community services [4] Collaboration with Insurance - The partnership with Aixin Life Insurance integrates insurance into the healthcare process, simplifying patient reimbursement and enhancing service efficiency [6] - The "medical + insurance" model aims to provide comprehensive health management and support for the elderly population [6] Future Outlook - The company expects total revenue to exceed 6 billion CNY in 2024, with an average net profit margin of around 9% [7] - The group has established several specialized elderly hospitals, with annual business growth exceeding 10%, and some hospitals achieving growth rates of up to 22% [7]

新里程健康科技集团股份有限公司 关于中证中小投资者服务中心《股东质询函》回复的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）于近 日收到中证中小投资者服务中心（以下简称"投服中心"）的《股东质询函》（投 服中心行权函〔2024〕40号），对公司近期公告拟以3.2亿元收购控股股东北京新 里程健康产业集团有限公司下属子公司北京新里程康养产业集团有限公司（以下 简称"新里程康养"）持有的重庆新里程医疗管理有限公司（以下简称"重庆新 里程"或"标的公司"）100%股权事项（以下称"本次收购"）涉及重庆新里程 历史股权交易信息披露问题尚存疑问，依法行使股东质询权。公司收到《股东质 询函》后高度重视，立即组织人员就《股东质询函》所提出的问题进行了核查分 析，现说明回复并公告如下： 问题："本次交易公告仅披露了重庆新里程历史沿革、出让方获得该项资产 的时间、方式及近三年又一期的股权变动情况，但未披露重庆新里程的历史股权 转让价格及评估情况等信息，请你公司根据公告格式规定补充披露相关信息，如 相关股权变动评估价 ...

新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2024-087 新里程健康科技集团股份有限公司 第六届监事会第二十一次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、监事会会议召开情况 。 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）第六 届监事会第二十一次会议通知于2024年10月18日以书面、电子邮件、电话送达等 方式发出，会议于2024年10月24日以现场表决结合通讯方式表决在公司会议室召 开。会议由公司监事会主席李海涛先生召集并主持，公司现任监事3名，实际表 决监事3名，符合《公司法》和《公司章程》的有关规定，会议决议合法有效。 二、监事会会议审议情况 经与会监事审议，会议审议通过了以下议案并做出如下决议： （一）审议通过《关于公司<2024 年第三季度报告>的议案》 具体内容详见公司2024年10月26日刊载于《证券时报》《证券日报》《中国 证券报》《上海证券报》和巨潮资讯网（http://www.cninfo.com.cn）的《2024年 第三季度报告》（公告编号：2024-08 ...

（一）审议通过《关于公司<2024 年第三季度报告>的议案》 新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2024-086 新里程健康科技集团股份有限公司 第六届董事会第二十七次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）第六 届董事会第二十七次会议于 2024 年 10 月 18 日以书面、电话、电子邮件等形式 发出，会议于 2024 年 10 月 24 日在公司会议室以现场表决结合通讯表决的方式 召开，本次会议由公司董事长林杨林先生主持，公司现任董事 11 名，实际表决 董事 11 名，公司监事及高级管理人员列席本次会议，会议的召开与表决程序符 合《公司法》和《公司章程》的有关规定，所做决议合法有效。 二、董事会会议审议情况 经与会董事充分讨论，审议通过了以下议案并形成决议。 董 事 会 二〇二四年十月二十六日 经审议，《2024年第三季度报告》内容真实、准确、完整地反映了公司的实 际情况，不存在任何虚假记载、误导性陈 ...

Financial Performance - Revenue for the third quarter of 2024 was RMB 860.51 million, a decrease of 4.43% year-over-year[3] - Net profit attributable to shareholders for the third quarter was RMB -7.35 million, an improvement of 68.84% year-over-year[3] - Total revenue for the period reached 2,680,748,437.88 RMB, an increase from 2,507,074,501.01 RMB in the previous period[19] - Operating profit for the period was 74,974,123.46 RMB, up from 41,224,104.30 RMB in the previous period[22] - Net profit for the period was 56,491,361.49 RMB, compared to 36,231,423.01 RMB in the previous period[22] - Net profit attributable to parent company shareholders increased to 52,794,403.83 from 33,418,091.37, showing significant growth[24] - Comprehensive income total rose to 56,491,361.49 from 36,231,423.01, indicating overall financial improvement[24] - Basic and diluted earnings per share both increased to 0.0155 from 0.0100, reflecting higher profitability[24] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 6.18 billion, an increase of 1.67% compared to the end of the previous year[3] - The company's equity attributable to shareholders increased by 5.35% to RMB 2.31 billion compared to the end of the previous year[3] - Total assets increased from RMB 6,080,204,990.53 at the beginning of the period to RMB 6,181,836,361.04 at the end of the period[17] - Total liabilities decreased slightly to 3,827,256,953.63 RMB from 3,845,698,741.33 RMB[18] - Total equity increased to 2,354,579,407.41 RMB from 2,234,506,249.20 RMB[18] - The company's accounts receivable increased from RMB 1,023,067,107.20 at the beginning of the period to RMB 1,138,802,108.35 at the end of the period[17] - The company's short-term borrowings increased from RMB 716,486,474.08 at the beginning of the period to RMB 768,919,420.76 at the end of the period[17] - The company's accounts payable increased from RMB 1,299,581,146.42 at the beginning of the period to RMB 1,376,434,469.67 at the end of the period[17] Cash Flow - Operating cash flow for the first nine months of 2024 was RMB 182.33 million, an increase of 1.68% year-over-year[3] - Cash received from sales of goods and services increased to 2,640,473,369.46 from 2,351,494,251.04, showing higher revenue generation[24] - Net cash flow from operating activities slightly increased to 182,332,848.56 from 179,311,770.70, indicating stable operational performance[26] - Cash paid for goods and services increased to 1,067,617,179.59 from 1,011,576,344.16, reflecting higher operational expenses[26] - Cash paid to employees increased to 817,701,013.62 from 797,093,862.36, showing higher labor costs[26] - Net cash flow from investing activities decreased to -248,129,070.99 from -249,957,842.42, indicating reduced investment outflows[26] - Net cash flow from financing activities turned negative to -169,193,739.50 from 104,954,507.18, reflecting higher debt repayments[27] - Ending cash and cash equivalents decreased to 322,031,481.64 from 572,507,320.47, showing a significant reduction in liquidity[27] Shareholder Information - Beijing New Journey Health Industry Group Co., Ltd. holds 24.23% of shares, totaling 825,927,323 shares[9] - Que Wenbin, an individual shareholder, holds 10.75% of shares, totaling 366,317,769 shares[9] - The company plans to repurchase shares using self-owned or raised funds, with a total amount ranging from RMB 50 million to RMB 100 million, at a price not exceeding RMB 2.74 per share, aiming to repurchase approximately 18,248,175 to 36,496,350 shares, accounting for 0.54% to 1.07% of the total issued shares[13] - As of September 30, 2024, the company has repurchased 5,607,000 shares, representing 0.1645% of the total shares, with a total transaction amount of RMB 10,017,709[13] - On October 21, 2024, the company repurchased an additional 4,320,000 shares, accounting for 0.1267% of the total shares, with a total transaction amount of RMB 10,662,758[13] - As of the report date, the cumulative repurchased shares amount to 9,927,000, representing 0.2913% of the total shares, with a total transaction amount of RMB 20,680,467[13] Expenses and Income - Non-recurring gains and losses for the third quarter amounted to RMB 3.42 million, primarily due to government subsidies and asset disposal losses[4][5] - The company's investment income increased by 235.02% to RMB 2.91 million due to the disposal of equity in affiliated enterprises[6] - Fair value change income was RMB 323,499, a 100% increase due to gains from newly acquired asset management products[7] - Credit impairment loss decreased by RMB 23,683,043.84, a 51.38% improvement due to recovery of previously recognized bad debts[7] - Income tax expense increased by RMB 13,477,005.38, a 297.02% rise due to reduced deferred tax expenses[7] - R&D expenses increased to 7,514,256.13 RMB from 6,905,702.82 RMB[22] - Sales expenses rose to 182,604,597.48 RMB from 140,961,195.18 RMB[22] - Management expenses decreased to 383,700,270.18 RMB from 440,128,431.58 RMB[22] - Financial expenses increased to 92,855,637.61 RMB from 82,996,082.04 RMB[22] - Interest income decreased to 2,578,136.88 RMB from 5,793,685.43 RMB[22] Investments and Loans - Long-term loans decreased by 36.46% to RMB 458.93 million, as some loans were reclassified to current liabilities[6] - Cash received from disposal of subsidiaries and other business units surged by RMB 1,850,521.54, an 86,158.93% increase[7] - Cash paid for acquisition of fixed assets, intangible assets, and other long-term assets increased by RMB 88,537,316.83, a 56.24% rise due to increased investment in Chongzhou Second Hospital's new campus[7] - Cash paid for investments doubled to RMB 3,000,000, a 200% increase from the previous period[7] - Cash received from borrowings decreased by RMB 349,400,000, a 33.39% drop compared to the previous period[7] - Cash paid for debt repayment increased by RMB 363,365,568.12, a 90.32% rise[7] Monetary Funds and Contract Liabilities - The company's monetary funds decreased from RMB 580,235,282.43 at the beginning of the period to RMB 434,651,599.42 at the end of the period[15] - Contract liabilities increased by 39.45% to RMB 4.26 million, reflecting an increase in unfulfilled contract payments[6]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2][6]. Core Insights - The acquisition of Chongqing New Mile Medical Management Co., Ltd. for 320 million yuan at a price-to-sales ratio of 1.0x initiates the process of injecting high-quality hospital assets from the controlling shareholder into the listed company [3][4]. - Chongqing New Mile is experiencing steady growth, with a revenue of 315 million yuan in 2023 and a compound annual growth rate (CAGR) of 12% from 2021 to 2023. The net profit for 2023 was 4.05 million yuan, with a net profit margin of 1.29% [4][6]. - The company has a strategic focus on integrating medical and elderly care services, addressing the aging population issue in Chongqing, and has received recognition as a "National Elderly-Friendly Hospital" [4][6]. Financial Projections - Revenue forecasts for 2024, 2025, and 2026 are 4.099 billion yuan, 4.891 billion yuan, and 5.840 billion yuan, respectively, with year-on-year growth rates of 14%, 19%, and 19% [6][7]. - The projected net profit for the same years is 122 million yuan, 226 million yuan, and 316 million yuan, reflecting significant growth rates of 298%, 85%, and 40% [6][7]. - The report anticipates a gradual improvement in profitability, with the price-to-earnings (P/E) ratio decreasing from 70x in 2024 to 27x in 2026 [6][7]. Market Data - As of October 23, 2024, the company's stock price is 2.51 yuan, with a market capitalization of approximately 8.555 billion yuan [4][6]. - The stock has a 52-week price range of 1.66 to 3.37 yuan, indicating potential for price appreciation [4][6].

Investment Rating - The report maintains a "Buy" rating for the company [2] Core Views - The company follows a dual-drive strategy of "medical + pharmaceutical" focusing on building regional medical centers and expanding its traditional Chinese medicine product line [2] - The company operates five regional medical centers with 3 tertiary hospitals and 7 secondary hospitals, with a bed utilization rate of around 90% and an average annual single-bed output of approximately 400,000 RMB [3] - The company plans to expand its bed capacity by adding over 2,000 beds and aims to increase the average annual single-bed output to 500,000-600,000 RMB [3] - The company's controlling shareholder, New Journey Group, plans to inject high-quality medical assets into the company within five years, with the first acquisition of Chongqing New Journey completed in October 2024 [4] - The company's revenue is expected to grow from 4.288 billion RMB in 2024 to 5.851 billion RMB in 2026, with net profit increasing from 135 million RMB to 380 million RMB during the same period [5] Medical Sector - The company has established five regional medical centers in Liaoning, Henan, Jiangsu, Jiangxi, and Sichuan, with a total of 8,000 beds [9] - The company's hospitals have a strong local market share, with some hospitals achieving a market share of 50% in their respective regions [12] - The company's hospitals have adapted well to the DRG/DIP payment system, with all DRG-implementing hospitals achieving medical insurance surpluses in the first half of 2024 [3] - The company plans to expand its bed capacity by adding over 2,000 beds, with some hospitals already opening new beds in 2022 [20] Pharmaceutical Sector - The company's flagship product, "Duyiwei Capsule," is included in the national essential drug list and has been incorporated into the national centralized procurement catalog, which is expected to drive volume growth [26] - The company has completed the first phase of technical transformation for Duyiwei Capsule, increasing its annual raw material processing capacity from 1,200 tons to 1,800 tons [26] - The company aims to achieve a compound annual growth rate of over 20% in revenue for its pharmaceutical sector in the next three years [26] Financial Projections - The company's revenue is projected to grow from 4.288 billion RMB in 2024 to 5.851 billion RMB in 2026, with net profit increasing from 135 million RMB to 380 million RMB during the same period [5] - The company's EPS is expected to increase from 0.04 RMB in 2024 to 0.11 RMB in 2026 [5] - The company's P/S ratio is projected to decrease from 2.05x in 2024 to 1.50x in 2026 [5] Asset Injection - The company's controlling shareholder, New Journey Group, plans to inject high-quality medical assets into the company within five years, with the first acquisition of Chongqing New Journey completed in October 2024 [4] - Chongqing New Journey has over 1,000 beds and generated revenue of 315 million RMB in 2023, with a net profit of 1.21 million RMB [4] - The acquisition of Chongqing New Journey is seen as the starting point for the injection of high-quality assets into the company [4]

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company plans to acquire 100% equity of Chongqing Xinlicheng Medical Management Co Ltd for RMB 320 million, which is expected to expand its operations [2] - Chongqing Xinlicheng has shown steady revenue growth with a compound annual growth rate exceeding 10% and is projected to become a regional medical group with a scale of 8-10 billion yuan in the next three years [3] - The acquisition will add 1,000 beds to the company, and future expansions are planned, including new hospital buildings and tumor centers [4] - The parent company, Xinlicheng Health Group, has completed profit-oriented reforms for 70% of its hospitals and plans to inject high-quality medical assets into the company within five years [5] Financial Forecasts - The company's revenue is projected to be RMB 3,993 million, RMB 4,400 million, and RMB 4,835 million for 2024, 2025, and 2026, respectively, with year-on-year growth rates of 11.2%, 10.2%, and 9.9% [9] - Net profit attributable to the parent company is expected to be RMB 128.2 million, RMB 184.1 million, and RMB 237.7 million for 2024, 2025, and 2026, respectively, with significant year-on-year growth rates [9] - The gross margin is forecasted to remain stable at around 30.4%-30.6% over the next three years [9] - ROE is expected to improve from 5.5% in 2024 to 9.0% in 2026 [9] Operational Highlights - Chongqing Xinlicheng operates over 1,000 beds and has established a comprehensive development model integrating elderly hospitals, elderly care centers, and home-based care services [3] - The company is actively expanding its bed capacity, with new hospital buildings and tumor centers under construction, expected to add significant bed capacity by 2026 [4] - The parent company manages nearly 30 hospitals and 200 grassroots medical institutions across 20 provinces, with a total bed capacity exceeding 20,000 [5] Valuation Metrics - The company's PE ratio is expected to decrease from 67.85 in 2024 to 36.60 in 2026, indicating improving valuation attractiveness [9] - EV/EBITDA is projected to decline from 18.11 in 2024 to 12.17 in 2026, reflecting better operational efficiency [9] - The company's PB ratio is forecasted to decrease from 3.74 in 2024 to 3.28 in 2026, suggesting a more favorable valuation [9]

新里程健康科技集团股份有限公司 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）于2024 年10月17日下午收到深圳市中级人民法院（以下简称"深圳中院"）邮寄的《拍 卖通知书》［（2024）粤03执恢596号］，获悉深圳中院将于2024年11月18日10时至 2024年11月19日10时止（延时除外）在京东网司法拍卖平台上公开拍卖被执行人 公司股东阙文彬先生持有的公司部分股份。现将有关情况公告如下： 证券简称：新里程 证券代码：002219 公告编号：2024-085 新里程健康科技集团股份有限公司 关于股东所持公司部分股份将被司法拍卖的提示性公告 一、股东股份拍卖情况 | 股东 | 是否为控 股股东或 | 本次涉及股 | 占其所 | 占公司总 | 是否为 限售股 | | 拍卖 | 拍卖 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 第一大股 东及其一 | 份数量（股） | 持股份 比例 | 股本比例 | 及限售 | ...